It's about, for example, patients with cancer being able to receive targeted treatment instead of chemotherapy, which, among other things, results in fewer side effects, says Jessica Stegrud, social policy spokesperson for the Sweden Democrats at a press conference.
The funds will go to the Genomic Medicine Sweden (GMS) network, which is a collaboration between, among others, the seven regions with university hospitals, SciLifeLab, the business community, and patient organizations. They will coordinate the introduction of precision medicine and improved diagnostics for healthcare and treatment of various diseases.
This is a stronger basic financing and a broadening of the area of precision medicine and precision health, says Minister of Health and Social Affairs Acko Ankarberg Johansson (KD) at the press conference.
Some of the focus areas that the funds will go to are acute leukemias in adults, childhood cancer, analysis of residual cancer after treatment, and improved treatment for rare diseases.
According to the Minister of Health and Social Affairs, it's not new money being announced, but now it's being described what it will be used for.
Genomic Medicine Sweden (GMS) is a Swedish national initiative that started in 2018 with the aim of giving more patients with cancer, rare genetic diseases, and infectious diseases throughout Sweden access to broad genetic analysis for better diagnostics and more individualized healthcare and treatment.
GMS is a collaboration between Sweden's seven regions with university healthcare and the seven universities with medical faculties in Gothenburg, Linköping, Lund, Stockholm, Umeå, Uppsala, and Örebro. GMS also involves various stakeholders in a broader collaboration: healthcare, universities, SciLifeLab, the business community, and patient organizations.
